ESR1 and breast carcinoma: Long‐term clinical observations found that estrogen receptor (ER)‐positive breast cancer maintains a significant risk of relapse even after more than 10 years of follow‐up,55 which suggests that ER‐positive breast cancer has a propensity for metastatic latency.